



GlaxoSmithKline Consumer Healthcare Ltd.
24-25 Floor, One Horizon Center
Sector 43, DLF Phase 5, Golf Course Road
Gurugram (Haryana), India - 122002

T +91 124 4336500
F +91 124 4336600
E contact.4.gsk@gsk.com
www.gsk.com

May 10, 2019

Corporate Relations (Listing Department)
The Bombay Stock Exchange Ltd.
Stock Exchange Towers
Dalal Street, Fort
Mumbai - 400 023

Manager - Listing Department
National Stock Exchange of India Ltd.
C – 1, Block G, Exchange Plaza
Bandra-Kurla Complex
Bandra (East)
Mumbai - 400 05

Dear Sir,

Sub: Outcome of the Board Meeting

In accordance with SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015, please note that the Board of Directors of the Company at its meeting held on May 10, 2019, had approved the Audited Financial results for the year ended March 31, 2019, a copy of which is enclosed for your reference and records.

Deloitte Haskins & Sells LLP, Statutory Auditors of the Company, has issued an Audit Report with Unmodified opinion on Audited Financial Results of the Company (Standalone and Consolidated) for the quarter and year ended March 31, 2019.

The aforesaid declaration is given pursuant to Regulation 33(3)(d) and 52(3)(a) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

The Board also recommended a Dividend at the rate of Rs. 105/- per equity share of Rs. 10 each. The Dividend, if approved by the shareholders in the ensuing Annual General Meeting scheduled to be held on Friday, August 2, 2019, will be paid to those members whose names appear in the Company's Register of Members and to those persons whose names appear as Beneficial owners as per the details to be furnished by National Securities Depository Limited and Central Depository Services (India) Ltd. as at the close of business hours on Friday, July 26, 2019. The dividend shall be paid to the entitled Members on or before September 1, 2019.

The Register of Members and Share Transfer Books will remain closed from Saturday, July 27, 2019 to Friday, August 2, 2019, both days inclusive for the purpose of Dividend and Annual General Meeting.

The 60th Annual General Meeting of the members of the Company will be held on Friday, August 2, 2019 at 9.30 a.m. at Punjab Public School Auditorium, The Punjab Public School (Senior Wing), Nabha 147 201 (Punjab).

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on May 10, 2019 had appointed Mr. P.V. Bhide (DIN :03304262) as an Additional and Independent Director, with effect from May 10, 2019 till the ensuing Annual General Meeting.

Details as required to be disclosed as per Clause 7 of Annexure 1 of SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 are as follows:


Serial No.	Particulars	Details
1.	Reasons for change viz. appointment, resignation, removal, death or otherwise	Appointment
2.	Date of appointment	May 10, 2019
3.	Brief Profile	Mr. Bhide, Science and Law graduate from Delhi University, has done his Master's in Business Administration from IGNOU. He is enrolled as an Advocate with Delhi Bar Council. Mr. Bhide joined the Indian Administrative Service in 1973 and has served for 37 years. He held a series of increasingly senior positions at the State and Central levels. He worked as Secretary for Department of Finance and then Department of Energy of Andhra Pradesh. He was a Deputy Secretary / Director in the Department of Economic Affairs, Ministry of Finance and served as Advisor to India's Executive Director to the International Board for Reconstruction and Development, Washington. Mr. Bhide then served as Additional Secretary / Special Secretary in the Ministry of Home Affairs of the Government before being appointed as Secretary in the Department of Disinvestment with the Ministry of Finance. Mr. P. Bhide retired as Secretary, Department of Revenue, Ministry of Finance in January 2010, a position which he held from June 2007

4.	Disclosure of relationships between directors	Nil
----	---	-----

Kindly take the above intimation on your records.

Thanking You

Yours faithfully
For GlaxoSmithKline
Consumer Healthcare Limited



Shanu Saksena
Company Secretary
M.No: FCS-9733

Encl: as above

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

Regd. Office: Patiala Road, Nabha - 147 201 (Punjab).

Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurugram- 122 002, Haryana.

Tel. No. 01765-306400; Fax No. 01765-220642

CIN: L24231PB1958PLC002257

Email ID: investor.2.co@gsk.com

Website: www.gsk-ch.in



Statement of Financial Results for the quarter and year ended March 31, 2019						(Rs. in Lakhs)
Particulars	For the quarter ended			For the year ended		
	31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018	
	AUDITED (Refer Note 6)	UNAUDITED	AUDITED (Refer Note 6)	AUDITED	AUDITED	
1 Income						
(a) Revenue from operations	12,86,06	11,16,82	11,79,58	47,82,01	43,77,05	
(b) Other income	1,22,89	1,24,25	84,17	4,32,60	2,57,41	
Total Income	14,08,95	12,41,07	12,63,75	52,14,61	46,34,46	
2 Expenses						
(a) Cost of materials consumed	3,60,68	3,60,44	3,15,90	13,80,30	12,51,96	
(b) Purchase of stock-in-trade	25,70	35,06	32,53	1,14,81	1,39,64	
(c) Changes in inventories of work-in-progress, stock-in-trade and finished goods	(10)	(68,36)	25,27	(58,92)	40,98	
(d) Excise duty	-	-	-	-	60,54	
(e) Employee benefits expense	1,64,83	1,56,72	1,37,59	6,44,62	5,27,73	
(f) Depreciation and amortisation expense	14,92	15,81	14,54	60,50	64,37	
(g) Other expenses						
(i) Advertising and promotion	1,90,86	1,34,90	1,69,26	6,02,25	5,46,73	
(ii) Others	2,25,61	2,59,53	2,49,00	9,57,98	9,26,12	
(h) Finance costs	20	21	77	78	2,03	
Total Expenses	9,82,70	8,94,31	9,44,86	37,02,32	35,60,10	
3 Profit before tax (1-2)	4,26,25	3,46,76	3,18,89	15,12,29	10,74,36	
4 Income tax expense						
(a) Current tax	1,39,16	1,23,97	1,04,25	5,27,93	3,61,91	
(b) Deferred tax	1,28	1,73	2,83	1,56	12,35	
Total tax expense	1,40,44	1,25,70	1,07,08	5,29,49	3,74,26	
5 Profit for the period (3-4)	2,85,81	2,21,06	2,11,81	9,82,80	7,00,10	
6 Other comprehensive income						
(i) Items that will not be reclassified to profit or loss						
Remeasurements of post-employment benefit obligations	(8,47)	3,25	12,66	10,83	25,49	
(ii) Income tax relating to items that will not be reclassified to profit or loss	2,96	(1,14)	(4,38)	(3,78)	(8,82)	
Total other comprehensive income, net of income tax	(5,51)	2,11	8,28	7,05	16,67	
7 Total comprehensive income for the period (5+6)	2,80,30	2,23,17	2,20,09	9,89,85	7,16,77	
8 Paid up equity share capital	42,06	42,06	42,06	42,06	42,06	
(Face value of Equity Shares)	10	10	10	10	10	
9 Earnings per share (of Rs 10/- each) (not annualised):						
(a) Basic	67.95	52.56	50.36	233.69	166.47	
(b) Diluted	67.95	52.56	50.36	233.69	166.47	

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

Regd. Office: Patiala Road, Nabha - 147 201 (Punjab).

Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurugram- 122 002, Haryana.

Tel. No. 01765-306400; Fax No. 01765-220642



CIN: L24231PB1958PLC002257

Email ID: investor.2.co@gsk.com

Website: www.gsk-ch.in

(Rs. in Lakhs)

Statement of assets and liabilities		
Particulars	As at March 31, 2019 AUDITED	As at March 31, 2018 AUDITED
ASSETS		
Non-current assets		
Property, plant and equipment	4,62,07	4,75,38
Capital work-in-progress	12,59	35,71
Intangible assets	-	15
Intangible assets under development	5,14	2,54
Financial assets		
i. Loans	21,45	16,28
ii. Other financial assets	21,52	21,71
Deferred tax assets (net)	1,13,89	1,15,45
Income tax assets (net)	1,55,81	1,77,91
Other non-current assets	8,20	5,53
Total non-current assets	8,00,67	8,50,66
Current assets		
Inventories	4,65,47	4,09,42
Financial assets		
i. Trade receivables	3,85,68	2,78,72
ii. Cash and cash equivalents	5,73,32	6,14,10
iii. Bank balances other than (ii) above	35,24,02	29,71,09
iv. Loans	17,57	14,80
v. Other financial assets	2,06,49	1,77,66
Employee benefits	13,90	15,83
Other current assets	80,97	80,38
Total current assets	52,67,42	45,62,00
Total assets	60,68,09	54,12,66
EQUITY AND LIABILITIES		
Equity		
Equity share capital	42,06	42,06
Other equity	40,52,66	34,43,06
Total equity	40,94,72	34,85,12
LIABILITIES		
Non-current liabilities		
Provisions	1,01,88	1,25,41
Employee benefit obligations	57,51	59,54
Total non-current liabilities	1,59,39	1,84,95
Current liabilities		
Financial Liabilities		
(i) Trade payables		
-Total outstanding dues of micro and small enterprises; and	41,49	8,80
-Total outstanding dues of creditors other than micro and small enterprises	9,11,12	9,97,36
(ii) Other financial liabilities	4,41,08	3,39,66
Provisions	2,75,60	2,77,59
Employee benefit obligations	46,59	36,79
Income tax liabilities (net)	10,10	-
Other current liabilities	88,00	82,39
Total current liabilities	18,13,98	17,42,59
Total liabilities	19,73,37	19,27,54
Total equity and liabilities	60,68,09	54,12,66

62

m

•Notes to the financial results:

1. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meeting held on May 10, 2019 and were subjected to an audit by the statutory auditors.
2. The above results have been prepared in accordance with the Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India.
3. Effective April 01, 2018, the Company has adopted Ind AS 115 'Revenue from Contracts with Customers'. The management has assessed that there is no significant impact in the revenue recognition on adoption of Ind AS 115.
4. Consequent to introduction of Goods and Services Tax (GST) with effect from July 01, 2017, Central Excise, Value Added Tax (VAT) etc. have been subsumed into GST. In accordance with Indian Accounting Standard, as applicable and Schedule III of the Companies Act, 2013, unlike Excise Duties, levies like GST, VAT, etc. are not part of Revenue. Accordingly, the figures for the year ended March 2018 are not strictly relatable to current year numbers.
5. As the Company's business activity falls within a single operating segment namely "Nutrition", the disclosure requirements of Ind AS 108 "Operating segment" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, are not applicable.
6. The figures of the quarter ended March 31, 2019 and March 31, 2018 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of respective financial years which were subjected to limited review.
7. On December 03, 2018, the Board of Directors of GlaxoSmithKline Consumer Healthcare Limited ("Company") approved a Scheme of amalgamation ("the Scheme") between the Company and Hindustan Unilever Limited ("HUL"), their respective shareholders and creditors subject to obtaining requisite regulatory and other approvals. On January 23, 2019, the Competition Commission of India ("CCI") approved the proposed amalgamation and the Company has received 'No Objection letter' from Bombay stock exchange and National stock exchange on February 18, 2019. The Scheme of amalgamation has been filed by the Company and HUL with the respective National Company Law Tribunals at Chandigarh and Mumbai. Presently, the Company is in the process of seeking requisite approvals.

With effect from the Appointed Date (as defined in the Scheme), the Company shall stand amalgamated into HUL and its Undertaking shall, pursuant to the provisions of Sections 230 to 232 and other applicable provisions, if any, of the Act, be and stand transferred to and vested in HUL, as a going concern without any further act, instrument, deed, matter or thing so as to become, the undertaking of HUL by virtue of and in the manner provided in the Scheme.

In view of above, these financial statements have been prepared on a going concern basis.
8. The Board of Directors at their meeting considered and recommended a final dividend aggregating to Rs. 4,41,58 lakhs @ Rs. 105 per share (nominal value Rs. 10 per share) for the financial year 2018-19 (final dividend paid for previous year Rs. 3,15,42 lakhs @ Rs. 75 per share).

Place: Gurugram
Date : May 10, 2019

AD

ON BEHALF OF THE BOARD OF DIRECTORS


Navneet Saluja
Managing Director
DIN: 2183350

INDEPENDENT AUDITOR'S REPORT


**TO THE BOARD OF DIRECTORS OF
GlaxoSmithKline Consumer Healthcare Limited**

1. We have audited the accompanying Statement of Financial Results of **GlaxoSmithKline Consumer Healthcare Limited** ("the Company"), for the year ended March 31, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related Ind AS financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such financial statements.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.


We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
 - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and Total comprehensive income and other financial information of the Company for the year ended March 31, 2019.



5. We draw attention to Note 7 of the financial results which describes about the status of Scheme of amalgamation and the basis of preparation of these financial results on a going concern basis. Our opinion is not modified in respect of this matter.
6. The Statement includes the results for the Quarter ended March 31, 2019 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Manjula Banerji
Partner

(Membership No. 086423)

Place: Gurugram,
Date: May 10, 2019

